- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 12.08. | Reviva Pharmaceuticals GAAP EPS of -$0.19 beats by $0.17 | 2 | Seeking Alpha | ||
| 12.08. | Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 178 | GlobeNewswire (Europe) | - U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback... ► Artikel lesen | |
| 10.07. | NSE - REVIVA PHARMACEUTICALS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 6 | SEC Filings | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.05. | Reviva Pharmaceuticals GAAP EPS of -$0.46 misses by $0.11 | 4 | Seeking Alpha | ||
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | 416 | GlobeNewswire (Europe) | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals sichert sich 10 Mio. US-Dollar und verlängert finanzielle Reichweite bis Q1 2027 | 1 | Investing.com Deutsch | ||
| 15.04. | Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 | 1 | Investing.com | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 637 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 396 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 25.03. | Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split | 2 | Insider Monkey | ||
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 230 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.03. | Reviva Pharmaceuticals raises $10 million in public offering | 1 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,480 | +0,92 % | DAX Gewinner am Dienstag: Bayer Aktie | Kursentwicklung und Chartanalyse | ||
| NOVO NORDISK | 40,250 | +0,14 % | Abnehmboom 2.0! BioNxt Solutions, Novo Nordisk und Nestlé wachsen im Milliardenmarkt! | Die Abnehmspritze hat nicht nur den Pharmamarkt verändert, sondern wirkt sich auch sukzessive auf die Lebensmittelbranche aus. Der verschreibungspflichtige Wirkstoff Semaglutid zur Behandlung von Typ-2-Diabetes... ► Artikel lesen | |
| ROCHE | 394,12 | -0,20 % | Roche sammelt 410 Mio. CHF ein - Neue Anleihe läuft bis 2036 | Stuttgart (www.anleihencheck.de) - Die Roche Holding begibt eine neue Kapitalmarktanleihe (ISIN CH1593191039/ WKN A4EZDZ) im Umfang von 410 Mio. CHF, so die Börse Stuttgart.Für Anleger aus dem Euroraum... ► Artikel lesen | |
| VIATRIS | 14,114 | -0,52 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,400 | -1,23 % | The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up. | ||
| QUANTUM BIOPHARMA | 2,740 | 0,00 % | Quantum Biopharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Aug. 21, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 62,10 | -1,77 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 13,300 | -2,21 % | Newron Pharmaceuticals: Der heikle Weg nach dem FDA-Treffen | ||
| FILANA THERAPEUTICS | 0,826 | +3,51 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,060 | +0,74 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| COMPASS PATHWAYS | 12,200 | 0,00 % | Vergiss Zulassungen! Wer zahlt für die Therapie? Diese 3 Biotech-Aktien zeigen, worauf es jetzt wirklich ankommt | ||
| OPKO HEALTH | 1,280 | 0,00 % | OPKO Health Secures $125 Million Financing Against Mazdutide Royalties | ||
| OPUS GENETICS | 3,420 | -1,16 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| AURINIA PHARMACEUTICALS | 14,460 | +1,69 % | Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036 | ||
| PROTHENA | 8,074 | +0,32 % | Prothena Corporation plc: Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,351 Euro und damit -0,20 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.